Alumis (NASDAQ:ALMS) Director James Tananbaum Acquires 200,000 Shares

Alumis Inc. (NASDAQ:ALMS) Director James Tananbaum acquired 200,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was bought at an average cost of $5.59 per share, with a total value of $1,118,000.00. Following the completion of the transaction, the director directly owned 2,234,129 shares in the company, valued at $12,488,781.11. The trade was a 9.83% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alumis Trading Up 2.5%

NASDAQ:ALMS opened at $6.57 on Thursday. Alumis Inc. has a twelve month low of $2.76 and a twelve month high of $10.49. The company has a market cap of $683.67 million, a PE ratio of -1.62 and a beta of -1.33. The company’s 50 day moving average is $4.61 and its two-hundred day moving average is $4.23.

Alumis (NASDAQ:ALMS) last released its earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The company had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $3.14 million. As a group, analysts expect that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Alumis

A number of institutional investors have recently made changes to their positions in ALMS. Russell Investments Group Ltd. raised its stake in shares of Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after acquiring an additional 4,894 shares during the period. Kera Capital Partners Inc. acquired a new stake in Alumis in the 2nd quarter valued at approximately $32,000. Police & Firemen s Retirement System of New Jersey lifted its stake in Alumis by 199.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock worth $32,000 after purchasing an additional 7,165 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Alumis by 173.7% during the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock worth $35,000 after purchasing an additional 7,467 shares in the last quarter. Finally, Western Wealth Management LLC purchased a new position in shares of Alumis during the second quarter worth $36,000.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Wall Street Zen lowered Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Morgan Stanley decreased their price objective on shares of Alumis from $23.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, August 15th. Wells Fargo & Company began coverage on Alumis in a research report on Friday, July 25th. They issued an “overweight” rating and a $17.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Alumis in a research note on Thursday, August 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a research note on Thursday, November 13th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.20.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.